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Summary
 Background Standard procedure in cases of ovarian cancer includes surgical treatment and 
complementary chemotherapy based on taxanes and platinum compounds. The 
results of such a procedure in advanced forms of cancer are still unsatisfactory. 
More accurate determination of the duration of remission with cancer patients 
is possible through the identiﬁ cation of prognostic factors. Currently adopted 
and extensively used prognostic factors include, among others, the age of the 
patient at the moment of the disease being diagnosed, the degree of clinical ad-
vancement, the size of the tumour remaining after surgery, the histological type 
of the neoplasm, and the volume of ﬂ uid in the peritoneal cavity. Among neo-
plasm markers the greatest importance is attributed to the CA 125 antigen, but 
continued efforts are being made in the search for new, more speciﬁ c and sen-
sitive markers.
 Aim The objective of the study presented herein was estimation of the prognostic sig-
niﬁ cance of the active form of EGFR in the serum of women with ovarian cancer 
in relation to their disease-free survival time.
 Materials/Methods The study was performed on 100 women treated for ovarian cancer in the course 
of four years. The concentration of the active form of EGFR was determined in 
the blood serum, prior to treatment, using commercial immunoenzymatic sets. 
Disease-free survival was deﬁ ned as the time elapsed from the completion of com-
plementary ﬁ rst-line chemotherapy till the appearance of clinical and/or bio-
chemical (CA 125>30 U/ml) symptoms of relapse of the neoplastic disease.
 Results The concentration of the active form of EGFR fell within the range of 
0.093–0.475 fmol/ml and did not show statistical signiﬁ cance with relation to 
disease-free time: the duration of the remission period was similar in patients 
with low as well as with high concentration of the active form of that receptor.
 Conclusions Examination of concentration of the active form of EGFR in blood serum prior 
to surgery does not display prognostic signiﬁ cance for prediction of the length 
of the period of remission or of disease-free survival.
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BACKGROUND
Ovarian cancer is one of the most frequent ma-
lignant tumours in the female population. It is 
responsible for approximately a third of the to-
tal incidence of malignancies of women. In spite 
of continued improvement and advances in im-
age-based diagnostics, in 75% of cases it is still di-
agnosed when in advanced form. At present, the 
probability of survival for 5 years from the mo-
ment the disease has been diagnosed does not 
exceed 46% [1], with an average of about 20–
30%. Standard procedure with ovarian cancer 
includes surgical treatment and complementa-
ry chemotherapy based on taxanes and platinum 
compounds. However, therapeutic effects in ad-
vanced forms of the disease are still unsatisfactory. 
First-line chemotherapy, administered according 
to the standard sequence, six cycles at three-week 
intervals, leads to regression of advanced ovarian 
cancer in over 80% of cases, and in 40–60% the 
regression is total. Nevertheless, the average dis-
ease-free survival time with such patients is rela-
tively short – the median of time free of progres-
sion is 18 months. In most patients a relapse of 
the disease occurs [2]. The limited effectiveness 
of standard chemotherapy is caused by the oc-
currence or development of ovarian cancer re-
sistance to the cytostatic agents applied [3].
Cellular factors that determine the appearance 
of resistance to the effect of cytostatic agents in-
clude, among others, membrane receptors relat-
ed to tyrosine kinase, located on the surface of 
ovarian cancer cells, such as the epidermal growth 
factor receptor EGFR. It occurs in the majority of 
normal cells of the human organism [4]. In the 
course of activation of EGFR there takes place 
the joining of a ligand to the extracellular do-
main of the receptor, followed by the formation 
of a dimer with participation of a second EGFR 
(homodimerization) or another receptor from 
the family of human epidermal receptors, HER, 
e.g. HER2/neu (heterodimerization), the proc-
ess ending with the activation of tyrosine kinase 
included in the EGFR [5]. Activated tyrosine ki-
nase catalyses phosphorylation of cytoplasmic 
proteins, triggering a cascade of intracellular 
reactions causing the growth and diversiﬁ cation 
of cells [5]. Activation of EGFR is manifested in 
the phosphorylation of tyrosine radicals of C-end 
fragment of the receptor [6]. Detection of phos-
photyrosine in EGFR is the essence of immuno-
chemical methods used for qualitative and quan-
titative estimation of the active form of EGFR in 
body ﬂ uids and tissues. Studies in vitro demon-
strated also a relation between excessive expres-
sion of that receptor and activation of cascade 
of signals leading to inhibition of programmed 
death of cells – apoptosis [7,8]. Disturbance in 
the regulation of EGFR is observed in solid ne-
oplasms, such as that of the large intestine or 
ovarian cancer.
Currently accepted and extensively employed 
prognostic factors include the age of the patient 
at the moment the disease is diagnosed, degree 
of clinical development, size of the tumour re-
maining after surgery, histological type of the 
neoplasm, and volume of ﬂ uid in the peritoneal 
cavity. Among neoplasm markers the greatest im-
portance is attributed to the CA 125 antigen, but 
continued efforts are being made in the search 
for new, more speciﬁ c and sensitive markers.
AIM
The objective of the study was estimation of 
the concentration of the active form of EGF in 
blood serum taken prior to surgery from wom-
en with ovarian cancer in relation to disease-
free survival.
MATERIALS AND METHODS
The study was performed on a group of 100 wom-
en aged 30 to 77 (median 52 years) treated for 
ovarian cancer at the 1st Chair and Department 
of Gynaecology, Medical University of Lublin. 
Following surgery, all the patients were subject-
ed to complementary chemotherapy based on 
paclitaxel and cisplatin. Cytostatic agents were 
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administered every 21 days, in 6 runs, in accord-
ance with the valid dosage schematics: paclitax-
el 135mg/m2 and cisplatin 75mg/m2. The de-
gree of clinical advancement of the disease was 
estimated following the FIGO classiﬁ cation [9]. 
Concentration of the CA 125 antigen, determined 
in the patients’ blood serum after surgery with the 
enzyme-immunoﬂ uorescence method (ELFA), 
fell within the range from 3.3 to 5730U/ml (nor-
mal range: 0–35U/ml). The mean value of CA 
125 concentration was 350.8U/ml, with a medi-
an of 27.8U/ml. Histopathology analysis of post-
surgery material showed 47 cases of serum can-
cer, 28 cases of mucinous cancer, and 25 cases of 
endometrioid cancer. Disease-free survival was 
deﬁ ned as the time elapsed from documented 
complete remission to the appearance of clini-
cal (estimated by means of clinical examination 
of image-based examination) and/or biochemi-
cal (increased concentration of CA 125 antigen 
in blood serum above standard levels) symptoms 
of neoplastic disease relapse.
Concentration of the active form of EGFR was 
estimated by examining blood serum taken pri-
or to surgery. Concentration of the active form 
of the EGF receptor was determined using the 
human Active EGF Receptor ELISA (Bender 
MedSystems) set with measurement sensitivity 
of 0.078fmol/ml. Immunoenzymatic analysis was 
performed in accordance with the instructions 
provided with the set. The analytical procedure 
comprised the following stages: dilution of sam-
ples and standard prior to determinations, incu-
bation, coupling with secondary mice antibodies 
coupled with horseradish peroxidase, repeated 
incubation, enzymatic reaction, reading of ab-
sorbance and calculation of results based on the 
calibration curve. Statistical analysis was made 
using R mathematical software with Design and 
Hmisc libraries covered by the Public Domain 
Licence.
RESULTS
Concentration of the active form of EGFR fell 
within the range from 0.093 to 0.475fmol/ml. The 
median was 0.105 fmol/ml, with RH skewness of 
results. The median was used for the division of 
the studied group of patients into those with low 
(<0.105fmol/ml) and high (≥0.105fmol/ml) con-
centration of active form of EGFR in the blood 
serum (Figure 1).
Concentration of the active form of EGFR in 
blood serum of ovarian cancer patients did not 
reveal signiﬁ cant differences related to the age 
of the patients, level of clinical advancement, his-
tological type of the neoplasm, degree of its di-
versiﬁ cation, concentration of CA 125 antigen, 
or size of tumour after surgery.
Post-operative treatment of ovarian cancer com-
bined with complementary chemotherapy permit-
ted total remission of the disease in 84 patients 
(84%). During the period of observation that 
ended on 31st December, 2004, from among the 
84 patients with complete remission a relapse of 
the disease was recorded in 32 patients (38.1%). 
In the case of 52 patients (61.9%) no relapse of 
the disease occurred by the end of the observa-
tion period. Data on the time elapsed between 
the end of treatment and end of the observation 
period in that group of patients were considered 
as sheared observations. The mean disease-free 
survival, calculated with the Kaplan-Meier esti-
mation method based on complete and sheared 
observations, was 36.2 months (95% interval of 
conﬁ dence: 31.2–41.2 months).
Concentration of the active form of EGFR in 
blood serum did not show any statistically signif-
icant relation with the duration of disease-free 
survival – the duration of remission was similar 
in patients with low and high concentrations of 
that form of the receptor (p=0.384) (Table 1, 
Figure 2).
DISCUSSION
Study and recognition of new prognostic factors 
permits more profound understanding of the 
nature of the pathological process and develop-
ment of new methods of treatment of neoplastic 
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Figure 1. Serum concentration of active EGFR form in our study 
group.
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diseases. Mammary cancer may be an example of 
this. The discovery of molecular prognostic fac-
tors, such as the oestrogen receptor or the HER 
2 receptor, led to a change in the tactics of mam-
mary cancer treatment, and to the development 
of a new drug – the monoclonal antibody block-
ing the HER 2 receptor – Herceptine [10,11]. 
Knowledge of new prognostic factors is also high-
ly signiﬁ cant in making important clinical deci-
sions concerning the treatment and the manner 
of informing a patient with cancer, or her fami-
ly. Estimation of the concentration of the active 
form of EGFR in blood serum of patients prior 
to treatment allows one to ﬁ nd out whether there 
is any possibility of obtaining valuable prognostic 
information before undertaking surgery aimed 
at reducing the mass of the tumour that is the 
source of the active form of EGFR.
Determination of the concentration of EGFR in 
blood serum was the subject of studies by Baron 
et al., who dealt with estimations of the level of 
EGFR as a potential marker of ovarian cancer that 
could be potentially used in the diagnostic process 
[12,13]. Those authors observed the occurrence 
of low concentrations of EGFR in ovarian cancer 
patients. The studies published by Baron et al., 
however, are concerned with the occurrence of 
the soluble form of EGFR that constitutes the ex-
tracellular domain of the receptor, released from 
the surface of cells. The study of the concentra-
tion of the active form of EGFR becomes possi-
ble when using a set in which the primary anti-
EGFR antibodies ﬂ atten the microplate and bind 
EGFR during the preliminary incubation, while 
antibodies reacting with areas of the receptor that 
are rich in phosphotyrosine are employed only 
at the second stage of the treatment. The active 
form of EGFR was present in each serum sample 
tested. Its concentration assumed values within 
the range from 0.093 to 0.475fmol/ml. The con-
centration did not depend on the examined clin-
ical and histological features of the ovarian can-
cer, nor did it display any signiﬁ cant prognostic 
value in any of the models analysed. The analy-
ses performed did not conﬁ rm pre-operative ef-
fectiveness of the active form of the receptor for 
EGF with respect to the prediction of disease-free 
survival of ovarian cancer patients. Examination 
of concentration of the active form of EGFR in 
blood serum prior to surgery does not display 
prognostic signiﬁ cance for the prediction of the 
length of the period of remission or of disease-
free survival in ovarian cancer women.
Prediction of disease-free survival in ovarian can-
cer patients is a complex clinical problem. The 
use of accepted prognostic factors, such the pa-
tient’s age, degree of clinical advancement of the 
disease, size of tumour after surgery, presence of 
ascites in the peritoneal cavity, type and degree 
of clinical advancement and concentration of 
CA 125, involves an excessive percentage of er-
roneous predictions. The necessity of searching 
for new molecular factors with prognostic signif-
icance will permit an increase in the number of 
correct predictions and may be conducive to the 
implementation of modern therapeutic methods 
of ovarian cancer treatment, based on the appli-
cation of monoclonal antibodies.
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Figure 2. Disease-free survival (in months) in relation to serum 
concentration of active EGFR form.
Active EGFR form serum 
concentration
Disease-free survival (in months)
p
x
_
±SE Range
Low 36.1±3.5 1–48
0.3843
High 33.1±3.9 3–51
Table 1. Disease-free survival (in months) in relation to serum concentration of active EGFR form. The results are presented as mean (x
_
) 
± standard deviation (SE) and range. Serum concentration of active EGFR form was not statistically correlated with disease-free survival 
(p>0.05).
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CONCLUSIONS
Examination of concentration of the active form 
of EGFR in blood serum prior to surgery did not 
display any signiﬁ cance for prediction of the 
length of disease-free survival for ovarian can-
cer patients.
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